

Domenico Mavilio, M.D., Ph.D,
Principal Investigator and Associate Professor
Head of Unit of Clinical and Experimental Immunology
Department of Medical Biotechnologies and Translational Medicine
Medical School of Milan University and Humanitas Research Hospital
email: domenico.mavilio@humanitas.it

domenico.mavilio@unimi.it domenico.mavilio@humanitas.it

Webpage: <a href="http://www.humanitas-research.org/category/principal-investigator/mavilio/">http://www.humanitas-research.org/category/principal-investigator/mavilio/</a>

**Education:** Domenico Mavilio, born in Brindisi (Italy) on May 22<sup>nd</sup> 1971, graduated as M.D. and completed his residency program in Internal Medicine/Respiratory Medicine at the Medical School of Genova University. He then obtained his Ph.D. in Clinical and Experimental Immunology within a joint program between the University of Genova and the National Institutes of Health (NIH) under the supervision of Alessandro Moretta and Anthony S. Fauci. He was then appointed as Research Fellow at NIH where he spent a total of 9 years before going back to his home country where he was appointed as Principal Investigator of the Unit of Clinical and Experimental Immunology (UCEI)at Humanitas Research Hospital (Milan, Italy). He also currently serves as an Associate Professor of Translational Medicine at Medical School of Milan University.

Research Interest, Funding and Leadership: As physician, Prof. Mavilio focuses his clinical activities on immunological disorders and hematologic malignancies. As a scientist, he handles research projects of translational medicine from the "bed-to bench" side aimed to study the pathogenesis and the cure of immunologic diseases. In particular, as the Principal Investigator and Head of UCEI, Prof. Mavilio investigates on both physiology and physiopathology of human innate immune system (i.e. Monocytes/Macrophages Natural Killer,  $\gamma\delta$  and dendritic cells) in several models of immune-mediated diseases including viral infections (HIV-1 and HCMV), auto-immune disorders and solid/hematologic cancers. These projects require the collection and the processing of several types of human specimens (peripheral blood, gut, liver, female genital tract, skin, primary and secondary organs, bone marrow). To this end, Prof Mavilio currently supervises a team of our research composed by 2 physicians, 2 Staff scientist, 1 post-doctoral fellows, 3 Ph.D. students, 1 laboratory manager, 1 technician and 6 undergraduate students. He also coordinates exchange programs of translational medicine with clinical units of immunology, infectious diseases, general surgery, plastic surgery, gynecology, urology and hematooncology. In this context, Prof. Mavilio's team is actively involved in ongoing scientific and clinical collaborations with universities and research institutes in Italy, United Kingdom, France, Portugal, Switzerland, USA and Colombia. His research programs are supported by Italian Ministry of Health, European Union, Italian Association for Cancer Research (AIRC), Cariplo Foundation, Umberto Veronesi Foundation, Humanitas Research Hospital and National Institutes of Health. In his professional career, Prof. Mavilio was supported both as P.I or Co. P.I by a total funding of more than 6 million euro. He published 81 articles on peer reviewed scientific journals and several book chapters (https://www.ncbi.nlm.nih.gov/pubmed/?term=mavilio+d) and he received several national and international prizes. His current impact factor is 27 and total number of citations is 3092 (Scopus). Prof. Mavilio also currently serves as Adjunct Investigator at NIH and is a board member of Ph.D. Program of Immunology of Milan University.

**Statement of Interest:** Prof. Mavilio is an active member of SLB since 2010 and served as associate and now deputy editor for JLB. He is a member of the Italian Society of Immunology, the faculties of Humanitas Research Hospital and Milan University. His affiliations to national/international scientific

societies and clinical institutions are key among his skills including i) creating collaborative and synergic research projects of translational medicine and ii) implementing networks between scientific communities to better disseminate biomedical research and educate new generations of scientists. Within JLB, in addition to peer-review duties, Prof. Mavilio organizes initiatives of science dissemination and training of young investigators such as serving as chairman of a translational immunology meeting in Italy. In addition, he has organized large clusters of papers from JLB meeting editions. This helps spread the highlights of these meetings and creates interactions between SLB and European scientific networks/societies. In 2019 he will host an SLB session on auto-inflammatory disease and a new cluster of papers at a meeting in Milan, Italy.

Prof. Mavilio's goal is to implement the above as an official member of SLB council. As a scientist in Italy, he aims to increase the existing synergies of SLB within Europe and expand these interactions in Eastern Europe and Asia. He hopes to work within SLB to organize summer schools of immunology/translational medicine/cellular biology to bring together young scientists, whose professional careers could be boosted by SLB through awards and publication opportunities and support in seeking research funding. This project will create a generation of SLB-associated scientists that will help the growth of our society.

If selected, Prof. Mavilio will use his best skills for enlarging the SLB community and its positive influence on the international scientific community.